Study of phenotype evolution during childhood in Marfan syndrome to improve clinical recognition

Genet Med. 2014 Mar;16(3):246-50. doi: 10.1038/gim.2013.123. Epub 2013 Sep 5.

Abstract

Purpose: Because diagnosis of Marfan syndrome is difficult during infancy, we used a large cohort of children to describe the evolution of the Marfan syndrome phenotype with age.

Methods: Two hundred and fifty-nine children carrying an FBN1 gene mutation and fulfilling Ghent criteria were compared with 474 non-Marfan syndrome children.

Results: Prevalence of skeletal features changed with aging: prevalence of pectus deformity increased from 43% at 0-6 years to 62% at 15-17 years, wrist signs increased from 28 to 67%, and scoliosis increased from 16 to 59%. Hypermobility decreased from 67 to 47% and pes planus decreased from 73 to 65%. Striae increased from 2 to 84%. Prevalence of ectopia lentis remained stable, varying from 66 to 72%, similar to aortic root dilatation (varying from 75 to 80%). Aortic root dilatation remained stable during follow-up in this population receiving β-blocker therapy. When comparing Marfan syndrome children with non-Marfan syndrome children, height appeared to be a simple and discriminant criterion when it was >3.3 SD above the mean. Ectopia lentis and aortic dilatation were both similarly discriminating.

Conclusion: Ectopia lentis and aortic dilatation are the best-discriminating features, but height remains a simple discriminating variable for general practitioners when >3.3 SD above the mean. Mean aortic dilatation remains stable in infancy when children receive a β-blocker.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adrenergic beta-Antagonists / therapeutic use
  • Aorta / pathology
  • Body Height
  • Child
  • Child, Preschool
  • Cohort Studies
  • Diagnosis, Differential
  • Dilatation, Pathologic / diagnosis
  • Ectopia Lentis / diagnosis
  • Female
  • Fibrillin-1
  • Fibrillins
  • Genetic Testing / methods
  • Genetic Testing / statistics & numerical data
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Marfan Syndrome / diagnosis*
  • Marfan Syndrome / drug therapy
  • Marfan Syndrome / genetics*
  • Microfilament Proteins / genetics*
  • Mutation
  • Phenotype
  • Reproducibility of Results
  • Sensitivity and Specificity

Substances

  • Adrenergic beta-Antagonists
  • FBN1 protein, human
  • Fibrillin-1
  • Fibrillins
  • Microfilament Proteins